Introduction {#sec0001}
============

Despite the increasing availability of biological and other innovative therapies, rheumatoid arthritis (RA) remains a major health problem [@bib0001], [@bib0002], [@bib0003]. Current treatment recommendations in clinical guidelines advocate intensive management using treat-to-target strategies \[[@bib0004], [@bib0005]\]. There is strong evidence these are effective in early RA patients with high disease activity [@bib0006], [@bib0007], [@bib0008], [@bib0009]. However, a large number of patients followed in specialist units who are receiving conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) continue to have moderately active established RA \[[@bib0010], [@bib0011]\]. Despite the known poor long-term outcomes of these patients, there is uncertainty whether they too will benefit from intensive management.

The TITRATE trial took place in routine care settings across multiple centres with management delivered by specialist nurses and other health care professionals who had completed a targeted two day training programme. It evaluated the effectiveness of intensive management in moderately active established RA. Based on monthly clinical assessments drug therapy was optimised and patients also received psycho-social support delivered by trained nurses and other practitioners using motivational interviewing techniques [@bib0012]. One previous trial in such patients, the British Rheumatoid Outcome Study Group (BROSG), undertaken in the pre-biological era [@bib0013]; found intensive management using csDMARDs achieved only modest increases in remission and the differences were not significant. North American experience with similar patients has been variable. Harrold et al. found no benefit from treat to target approaches [@bib0014]. In contrast studies by Solomon et al. found benefit after training clinicians involved in general principles of management [@bib0015], [@bib0016], [@bib0017]. Uncertainty about the benefits of intensive management in moderately active established RA remains an important challenge when generalising treat-to-target approaches [@bib0018].

The TITRATE trial bridges this evidence gap by testing the hypothesis that 12-months of intensive management in patients with established moderately-active RA given in conjunction with psychosocial support provides more remissions than standard care.

Patients and methods {#sec0002}
====================

Design {#sec0003}
------

An open-label, 12-month, pragmatic, randomised, multicentre, two-arm, parallel group superiority trial.

Participants {#sec0004}
------------

Patients were recruited from 39 English rheumatology centres. Included patients comprised: males and females over 18 years; who met 2010 RA classification criteria [@bib0019]; had received ≥6 months csDMARDs; were currently receiving at least one csDMARD; had moderate/ intermediate disease activity (DAS28-ESR 3.2--5.1 with three or more swollen and/or tender joints out of 66/68 and at least one swollen joint); were able and willing to follow intensive management. Patients were excluded who had comorbidities making treatment intensification inadvisable (e.g. heart failure); had failed ≥5 csDMARDs; received biologics; had irreversible disability from extensive joint damage; were pregnant, breast-feeding or women planning to conceive; had recently participated in another clinical trial; and were currently on early RA management pathway.

Interventions {#sec0005}
-------------

Drug treatment complied with guidance from the National Institute for Health and Clinical Excellent (NICE) and the national specialist society (British Society for Rheumatology).

*Standard Care:* clinicians followed local pathways for managing moderate disease activity patients reflecting national guidance \[[@bib0020], [@bib0021]\] without specific treatment and follow-up plans.

The approach for managing RA in England when the trial was undertaken involved optimising csDMARD monotherapy, considering combination therapy with csDMARDs, and giving biologics if patients had active disease despite failing to respond to two csDMARDs.

*Intensive Management:* this was delivered by nurses and allied healthcare professionals who had completed a 2-day training to follow a pre-defined treatment support programme [@bib0022]. Monthly for 12 months they: (a) assessed disease activity; (b) reviewed drug treatment; (c) modified drug treatment using a decision tool reflecting "shared treatment plans" formulated with patients during their first visit; and (d) provided supportive psychosocial care.

Intensive Management spanned four strands: (i) providing information about RA with a handbook outlining treatments, side effects and ways to cope with RA; (ii) optimising drug treatment with csDMARDs and biologics using a treatment algorithm; (iii) giving intra-muscular glucocorticoids if arthritis not fully controlled; and (iv) providing "treatment support" focussing on pain and fatigue management; physical activity; medication adherence, sleep and mood. Treatment support used techniques taken from motivational interviewing (MI) \[[@bib0023], [@bib0024]\]. Intensive management consultations were audio recorded by rheumatology practitioners with patients' consent. A 10% sample of all recorded consultations were assessed against a fidelity checklist developed for TITRATE [@bib0012] to monitor the delivery of MI techniques [@bib0025].

*Primary Outcome:* DAS28-ESR remission (DAS28-ESR \<2.6) at 12 months [@bib0026].

*Secondary Outcomes:* alternative measures of remission (DAS28-CRP \<2.6, SDAI≤3.3, CDAI≤ 2.8 and ACR/EULAR Boolean remission) \[[@bib0026], [@bib0027]\]) and low disease activity (DAS28-ESR ≤3.2) at 12 months; tender (28/68) and swollen joint counts (28/66); erythrocyte sedimentation rate (ESR); C-reactive protein (CRP); patient global and assessor global assessments on 100 mm visual analogue scales (VAS); pain and fatigue on 100 mm VAS; health assessment questionnaire (HAQ) [@bib0028]; EuroQoL 5 Dimensional score (EQ5D-5 L) [@bib0029]; plain-film X-rays of hands and feet scored using modified Larsen\'s scores [@bib0030]; NHS and personal social service costs measured by modified Client Service Receipt Inventory (CSRI) questionnaires [@bib0031].

Assessments {#sec0006}
-----------

An anonymised electronic data capture system collected clinical data. Demographic measures were recorded at baseline. Clinical outcomes were assessed 6- monthly; X-rays were taken and assessed annually.

Sample size {#sec0007}
-----------

The most relevant UK treat-to-target trial in active early RA had found 16% of standard care patients achieved end-point DAS remissions [@bib0032]. We assumed 16% of standard care patients in TITRATE would similarly achieve endpoint DAS28-ESR remission. We proposed rejecting the null hypothesis (intermediate disease activity RA patients receiving csDMARDs have no more remission after 12-months intensive management) if remission rate increased by ≥15%. Showing this difference with 5% significance level and 90% power indicated the need to randomise 358 patients. Recruitment ended after three years for organisational reasons with 335 patients randomised (94% planned sample size) [@bib0012].

Randomisation {#sec0008}
-------------

Potentially eligible patients were screened and reasons for non-entry recorded. Consenting patients were individually randomised using block randomisation with randomly varying block sizes. Stratifying by site ensured pre-randomisation allocation concealment. Patients were randomised to intensive management or standard care in a 1:1 ratio. Trial staff were unaware of the allocation sequence.

Blinding {#sec0009}
--------

TITRATE was un-blinded; patient involvement in intensive management made blinding impossible. Independent assessors uninvolved in managing trial patients undertook follow up clinical assessments. Pain, fatigue, disability and quality of life were self-assessed by patients. X-ray reading was performed blinded to treatment.

Statistical methods {#sec0010}
-------------------

Randomised patients who received treatment were assessed on an intention-to-treat (ITT) basis following CONSORT guidelines [@bib0033]. All participants had complete observations at baseline. Missing observations during follow-up (Supplementary Table 1) were multiply imputed regardless of the reason(s) they were missing. Predictive mean matching with five nearest neighbours, assuming unobserved measurements were missing at random was used to impute primary and secondary outcomes. Sensitivity analysis assessed the robustness of the missing at random assumption using pattern-mixture model approach (Supplementary Table 2); it showed qualitatively similar results; consequently, only the primary multiple imputation analyses are reported. A complete case analysis was also undertaken.

Logistic regression analysis was used to evaluate the effect of Intensive Management treatment on the primary outcome (12-month remission) and other binary outcomes. "Univariable" analyses of treatment were adjusted for NHS region (design variable). "Multivariable" analyses further adjusted for gender, ethnicity, age and disease duration. Linear regression evaluated change from baseline to 12-months for the continuous outcomes. Linear mixed models estimated the effect of treatment over follow-up time; working correlation matrices were unstructured as measurements were taken at three time points (i.e. baseline, 6 and 12 months). Interactions between time and treatment group were assessed in these models and were found not to be significant at 5% level and thus the main effect of treatment is reported in the various linear mixed effects analyses after dropping the time by treatment interaction. Serious and other adverse events were evaluated using comparisons of two independent proportions. Analyses were undertaken using Stata 16 [@bib0034].

Economic analyses {#sec0011}
-----------------

NHS and personal social service costs measured from patient resource use questionnaires and NHS hospital records; and adverse events. Total costs and quality-adjusted life years were measured using the EuroQol and combined to assess the health economic effects of intensive management compared with standard care, which was represented by an incremental cost-effectiveness ratio, see (Supplementary Table 3).

Ethics approval {#sec0012}
---------------

Ethical approval for this trial was obtained from the London -- West London & GTAC

National Research Ethics Service (NRES) Committee (13/LO/1308). All participants provide written informed consent before participating in the trial or extension study.

Results {#sec0013}
=======

Patients and treatments {#sec0014}
-----------------------

*Recruitment:* Between August 2014 and July 2017, 1405 patients were invited to participate: 459 patients were screened; 335 patients were randomised and treated ([Fig. 1](#fig0001){ref-type="fig"} ). 303/335 (90%) randomised patients provided 12-month primary outcomes, including 3 patients who withdrew but agreed to medical reviews ([Fig. 1](#fig0001){ref-type="fig"}).Fig. 1CONSORT diagram for TITRATE Trial.Fig 1

*Baseline Data and Numbers Analysed:* demographic and disease assessments were similar in both groups ([Table 1](#tbl0001){ref-type="table"} ). The intention to treat analysis included all 335 randomised patients (168 intensive management/167 standard care); the complete case analysis assessed 258 patients (134 intensive management/124 standard care).Table 1Baseline Characteristics, Assessments And Treatments.Table 1AssessmentsIntensive ManagementStandard Care*n* *=* *168n* *=* *167Demographic*Age (Years)56.4 (12.2)56.8 (12.0)Disease Duration (Years)6.6 (7.0)5.2 (5.5)Female (%)140 (83%)130 (78%)*Clinical Assessments*DAS28-ESR4.4 (0.5)4.3 (0.5)DAS28-CRP4.5 (0.6)4.5 (0.6)CDAI19.7 (6.5)20.4 (6.8)SDAI20.6 (6.3)21.1 (6.6)Tender Joint counts (68 joints)12 (9)13 (9)Swollen joint counts (66 joints)6 (5)5 (4)Erythrocyte Sedimentation Rate (mm/hr)18 (14)15 (13)C-Reactive Protein (mg/L)8 (11)7 (8)Assessor Global Rating (mm)39 (18)41 (18)Patient Global Assessment (mm)43 (19)46 (21)Fatigue VAS (mm)59 (25)52 (25)Pain VAS (mm)40 (23)43 (23)Health Assessment Questionnaire1.2 (0.7)1.2 (0.7)EQ5D-5L0.71 (0.16)0.70 (0.19)Larsen Score11 (17)9 (11)*Drug Treatments*Oral Methotrexate59 (35%)67 (40%)Subcut Methotrexate22 (13%)19 (11%)Sulfasalazine30 (18%)19 (11%)Leflunomide12 (7%)11 (7%)Hydroxychloroquine29 (17%)37 (22%)Azathioprine1 (1%)--Oral Methotrexate/Hydroxychloroquine7 (4%)8 (5%)Oral Methotrexate/Sulfasalazine2 (1%)1 (1%)Subcut Methotrexate/Hydroxychloroquine3 (2%)2 (1%)Subcut Methotrexate/Sulfasalazine2 (1%)--Sulfasalazine/Hydroxychloroquine1 (1%)3 (2%)[^1]

*Baseline Treatments:* all patients took at least one csDMARD; 15/168 (9%) of intensive management patients and 14/168 (8%) of standard care patients took two. Methotrexate, the main csDMARD, was taken by 81 intensive management and 86 standard care patients and as part of csDMARD combinations in another 14 and 11 patients respectively ([Table 1](#tbl0001){ref-type="table"}).

*Standard Care arm:* 128 patients started another csDMARD, 35 a second and 2 a third. csDMARD doses were increased in 32 patients and decreased in 9. Biologics were started in 24 patients; 2 had a second biological. biological doses were not increased in any patient and were reduced in one during the study period. Depot steroid injections were given to 50 patients: 28 received one injection; 19 received 2--4 injections and 3 had 5 or more injections ([Table 2](#tbl0002){ref-type="table"} ).Table 2Additional Treatments During Trial Follow Up.Table 2Intensive ManagementStandard CareAdditional drugsOral MTXSubcut MTXSSZLEFHCQOral MTXSubcut MTXSSZLEFHCQ*n* *=* *68n* *=* *27n* *=* *31n* *=* *12n* *=* *29n* *=* *76n* *=* *21n* *=* *22n* *=* *11n* *=* *37*None13 (19%)4 (15%)3 (10%)--2 (7%)20 (26%)5 (24%)7 (32%)3 (27%)--One DMARDs23 (34%)12 (44%)12 (39%)3 (25%)5 (17%)33 (43%)12 (57%)9 (41%)5 (45%)18 (49%)Two DMARDs13 (19%)6 (22%)11 (35%)5 (33%)9 (31%)14 (18%)1 (5%)5 (23%)--11 (30%)Etanercept16 (24%)4 (15%)4 (13%)4 (42%)9 (31%)4 (5%)1 (5%)1 (4%)2 (18%)4 (11%)Benepali1 (1%)1 (4%)1 (3%)--1 (4%)2 (3%)--------Other TNF Inhibitor2 (3%)------3 (10%)3 (4%)2 (10%)--1 (9%)4 (11%)[^2]

*Intensive Management arm:* 161/168 patients randomised to intensive management attended ≥1 session, with 7 missing all sessions: 3 changed from intensive management to standard care after their first visit; 4 withdrew from the study and were lost to follow up. 139/161(86%) patients attended at least 8 of the planned sessions (mean 11, SD 1.34) and 22/161 (14%) patients attended fewer than 8 visits (mean 4, SD 1.94).

One hundred and forty patients started another csDMARD, 64 a second and 3 a third. csDMARD doses were increased in 69 patients and decreased in 15. Biologics were started in 46 patients: 7 had a second biological and 2 had a third biological. biological doses were increased in 2 patients and reduced in two during the study period. Depot steroid injections were given to 72 patients: 22 received one injection; 33 received 2--4 injections and 17 ≥ 5 injections ([Table 2](#tbl0002){ref-type="table"}).

A total of 126 sessions were assessed for fidelity to the MI techniques. The data represented that of 42 patients across 19 research sites and 25 trained rheumatology practitioners. Fidelity assessments demonstrated 4 (3%) had poor fidelity to the taught techniques, 52 (41%) low fidelity, 58 (46%) moderate fidelity, and 12 (10%) high fidelity [@bib0025]. However, some approaches were undertaken with moderate or high fidelity, such as affirming the patient\'s strengths and abilities were observed at moderate or high-fidelity levels.

Primary outcome {#sec0015}
---------------

Intensive management increased 12-month DAS28-ESR remissions ([Table 3](#tbl0003){ref-type="table"} ) compared to standard care \[32% (95% CI: 25%, 40%) vs 18% (12%, 24%)\]. The differences were significant in both unadjusted and adjusted logistic regression analyses (*P*\<0.01).Table 3Remission rates with Intensive Management in Intention to Treat Population. The groups were compared using unadjusted and adjusted odds ratios.Table 3Remission ClassificationIntensive ManagementStandard CareUnadjustedAdjusted[\*](#tb3fn1){ref-type="table-fn"}Proportion (95% CI)Proportion (95% CI)OR (95% CI)*P*-valueOR (95% CI)*P*-valueDAS28-ESR32% (25%, 40%)18% (12%, 24%)2.17 (1.28, 3.68)0.0042.38 (1.36,4.17)0.002DAS28-CRP21% (15%, 27%)10% (5%, 15%)2.44 (1.27, 4.70)0.0082.52 (1.28,4.99)0.008SDAI17% (11%, 23%)10% (6%, 15%)1.81 (0.94, 3.47)0.0741.90 (0.97,3.72)0.060CDAI18% (12%, 24%)10% (6%, 15%)1.92 (1.00, 3.68)0.0492.10 (1.07,4.09)0.030ACR/EULAR Boolean13% (8%, 18%)6% (2%, 10%)2.32 (1.04, 5.18)0.0402.44 (1.06,5.64)0.036[^3]

Other remissions and low disease activity {#sec0016}
-----------------------------------------

There were greater proportions of 12-month remissions in DAS28-CRP, SDAI, CDAI and ACR/EULAR Boolean with intensive management (21%, 17%, 18% and 13%) than standard care (10%, 10%, 10% and 6%) ([Table 3](#tbl0003){ref-type="table"}).

Low disease activity states at 12 months were achieved by 48% (39%, 56%) on intensive management and in 32% (25%, 40%) of standard care patients. The difference was statistically significant \[unadjusted odds ratio 1.94 (1.22, 3.10) *P* = 0.005\], \[adjusted odds ratio 2.04 (1.25, 3.31) *P* = 0.004\].

Mean changes in the DAS28-ESR scores at 12 months from baseline were lower −0.57 (95% CI: −0.88, −0.26; *P*=\<0.001) in unadjusted; −0.51 (−0.81, −0.21; *P* = 0.001) in adjusted regression analyses with intensive treatment ([Table 4](#tbl0004){ref-type="table"} ). There were significant differences in DAS28-CRP, SDAI and CDAI 12-months change scores, tender and swollen joint counts, and assessor and patient global 12-months change scores between treatment arms. However mean ESR and C-reactive protein levels were unchanged during the trial without significant difference between groups at 12 months. There was only a small improvement in disability as assessed by HAQ and quality of life assessed by mean EQ5D; the difference between groups were not significant ([Table 4](#tbl0004){ref-type="table"}).Table 4Clinical Assessments At 12 Months In Intention To Treat Population. Estimated treatment effects are shown between trial arms.Table 4AssessmentIntensive ManagementStandard CareLinear Regression[\*](#tb4fn1){ref-type="table-fn"}Mixed Effect Models*N* *=* *168N* *=* *167*Unadjusted*P*-valueAdjusted*P*-valueUnadjusted*P*-valueAdjusted*P*-valueMean (SE)Mean (SE)CoefficientsCoefficientCoefficientsCoefficient(95% CI)(95% CI)(95% CI)(95% CI)DAS28-ESR3.4 (0.1)3.8 (0.1)−0.6 (−0.9, −0.3)\<0.001−0.5 (−0.8, −0.2)0.001−0.4 (−0.7, −0.2)0.001−0.4 (−0.6, −0.1)0.003Tender Joints7.5 (0.7)10.8 (0.8)−2.4 (−4.4, −0.3)0.023−2.7 (−4.5, −0.8)0.004−1.4 (−3.4, 0.7)0.187−1.7 (−3.5, 0.2)0.076Swollen joints3.5 (0.4)4.9 (0.5)−1.9 (−3.0, −0.7)0.002−1.6 (−2.7, −0.5)0.004−1.5 (−2.6, −0.5)0.005−1.3 (−2.3, −0.4)0.006ESR17 (1)15 (1)−1.5 (−3.9, 1.0)0.239−1.1 (−3.4, 1.1)0.329−1.1 (−3.2, 1.0)0.312−0.7 (−2.7, 1.2)0.463CRP9 (2)7 (1)0.9 (−2.6, 4.4)0.6281.5 (−1.8, 4.7)0.3720.6 (−2.0, 3.1)0.6661.3 (−0.9, 3.5)0.239Assessor Global23 (2)31 (2)−6 (−12, −0.2)0.043−8 (−13, −3)0.003−4 (−9, 2)0.169−5 (−10, −1)0.015Patient Global29 (2)41 (2)−9 (−15, −2)0.010−11 (−17, −6)\<0.001−6 (−12, −1)0.026−9 (−14, −4)\<0.001Fatigue40 (2)50 (2)−18 (−24, −11)\<0.001−15 (−21, −9)\<0.001−16 (−21, −10)\<0.001−13 (−18, −8)\<0.001Pain28 (2)37 (2)−6.5 (−13., 0.4)0.064−8.4 (−15, −2.3)0.007−4 (−11, 2)0.161−6 (−12, −1)0.015HAQ1.0 (0.1)1.1 (0.1)−0.1 (−0.2, 0.0)0.055−0.1 (−0.2, 0.0)0.046−0.1 (−0.1, 0.0)0.136−0.1 (−0.2, 0.0)0.137EQ5D-5L0.76 (0.02)0.72 (0.02)0.02 (−0.02, 0.06)0.2480.03 (−0.01, 0.07)0.0780.02 (−0.01, 0.05)0.2750.02 (−0.01, 0.05)0.121Larsen score13 (1)10 (1)0.5 (−0.1, 1.0)0.0950.4 (−0.2, 0.9)0.175--------[^4]

Mean pain and fatigue scores were significantly lower with intensive management in unadjusted and adjusted linear regression analyses ([Table 4](#tbl0004){ref-type="table"}). Clinically meaningful improvements in fatigue (10 units or more) were achieved by 58% (95% CI: 51%, 66%) of patients receiving intensive management and 35% (95% CI: 28%, 42%) of patients receiving standard care; logistic regression showed this difference was significant \[adjusted odds ratio 2.81 (1.76, 4.48) *P*\<0.001\]. Larsen X-ray scores increased from mean 11 to 13 with intensive management and 9 to 10 with standard care; with no significant differences between groups ([Table 4](#tbl0004){ref-type="table"}).

Longitudinal clinical outcomes {#sec0017}
------------------------------

Longitudinal analyses (over the three time points) assessed the overall impact of treatment over time using mixed effects models ([Table 4](#tbl0004){ref-type="table"}). Unadjusted and adjusted analyses showed significant differences between treatment groups for DAS28-ESR, swollen joint counts for 66 joints, patient global assessments, fatigue and pain. The treatment effects on fatigue between groups were particularly large; −15.7 (95% CI: −21.3, −10.1) in unadjusted and −13.1 (−18.1, −8.1) in adjusted analyses.

Complete case analyses {#sec0018}
----------------------

The effect of intensive management on remission and clinical outcomes was maintained in the complete case analyses (data not shown). Additional regression analyses showed no evidence that the use of steroids or biologics had an identifiable impact on 12-month remission rates or mean DAS28-ESR, pain or fatigue

An additional exploratory analysis showed that patients who had 11 or 12 intensive management visits achieved the best outcomes in terms of remissions and falls in 12-month DAS28-ESR, pain and fatigue scores (Online Supplementary Figure).

Adverse events {#sec0019}
--------------

There were 26 serious adverse events involving 24 patients: 15 with intensive management and 11 with standard care ([Table 4](#tbl0004){ref-type="table"}); there was no significant difference in the proportion of serious adverse events between treatment groups (Chi-squared=0.64; DF=1; *P* = 0.42). Three patients died: two on intensive management and one on standard care; no death was considered treatment related. Other serious adverse events spanned several systems; there was no indication any were treatment related ([Table 5](#tbl0005){ref-type="table"} ).Table 5Adverse Events In TITRATE Trial.Table 5CategoryBody SystemIntensive ManagementStandard Care*Deaths*CardiovascularRuptured thoracic aneurysm--NeoplasiaMetastatic cancer--Respiratory--Pulmonary fibrosis*Other Individual Serious Adverse Events*Allergy--AngioedemaCardiovascularHeart failureMicrovascular anginaMyocardial InfarctionParoxysmal arrhythmiaDyspnoea/chest tightness--Hypotension headache--GastrointestinalSmall bowel obstructionDiverticular disease--Diverticulitis--GallstonesNeoplasia--Breast cancerImmunologicalTonsillitis with neutropenia--MusculoskeletalRA flare/shoulder capsulitis--NeurologicalStrokeSepsisOtherPregnantDizziness/syncopeCollapsed unknown cause--Cerebral spinal fluid leak--RespiratoryChest infection/AsthmaExacerbation of Asthma*All Other Adverse Events*Number114 Episodes151 EpisodesAllergies1 (1%)3 (2%)Dermatological8 (7%)17 (11%)Cardiovascular5 (4%)8 (5%)Eyes, Ear, Nose & Throat10 (9%)15 (10%)Gastro-Intestinal9 (8%)27 (18%)Genitourinary/Renal3 (3%)10 (7%)Haematological5 (4%)3 (2%)Hepatic6 (5%)2 (1%)Immunological2 (2%)1 (1%)Musculoskeletal21 (18%)17 (11%)Neoplasia1 (1%)3 (2%)Neurological11 (10%)6 (4%)Other10 (9%)8 (5%)Psychological0 (0%)2 (1%)Respiratory22 (19%)29 (19%)

Overall, 132 patients (60 intensive management; 72 standard care) had 265 adverse events (114 intensive management; 151 standard care) ([Table 5](#tbl0005){ref-type="table"}). There was no evidence intensive management increased adverse event risks; in fact, a smaller proportion of patients with adverse events and a lower frequency of adverse events were reported in the intensive management arm.

Cost-Effectiveness {#sec0020}
------------------

Economic analysis showed the base case incremental cost-effectiveness ratio was £43,972 (€51,474) from medical and personal social service cost perspectives; the probability of meeting the English willing to pay threshold (£30,000/€35,000) was 17%. The incremental cost-effectiveness ratio fell to £29,363 (€24,384) after including patients' personal costs and lost working time; this corresponded to 50% probability intensive management is cost-effective at English willing to pay thresholds, see (Supplementary Table 4).

Discussion {#sec0021}
==========

The TITRATE trial showed that intensive management using treat-to-target principles in patients with established moderate RA gave substantially more remissions than standard care and more patients achieved a low disease activity state. Intensive management improved joint counts, global assessments of disease activity, fatigue and pain compared with standard care, though neither ESR nor C-reactive protein level were seen to fall with intensive management. There was no evidence intensive management led to more harms. There were numerically more serious adverse events with intensive management than standard care but fewer other adverse events with no significant differences between groups. Although we cannot be certain that in a large study the difference in serious adverse events may be significant, we think this is unlikely because previous systematic reviews of combination DMARD therapies\[35\] and treat to target trials [@bib0008] showed no increases in adverse events in many of these trials.

Economic analysis showed that the incremental cost-effectiveness from a medical and personal social service cost was above current willing to pay thresholds for medical cost in England. That said, our analysis was based on the historic cost of biological treatment when the trial was undertaken; biological acquisition costs have halved since biosimilars were introduced making the current cost-effectiveness of intensive management much more acceptable. The recent move towards telephone and video consultations as a consequence of the Coronavirus Pandemic will also decrease the costs of intensive management. In addition, taking account of patients' costs and the loss of working time also makes intensive management far more cost-effective.

In strategy trials like TITRATE, patients receive many interventions, with uncertainty about which of them contribute most benefit. Changing csDMARDs, starting biologics and providing psychosocial care may all have contributed; we cannot know which was most important. However, as a recent systematic review of different nurse interventions showed no evidence they specifically reduced disease activity compared to standard care [@bib0036], it is likely that patients benefit most when intensive drug treatment is combined with psychosocial care.

There has been debate about combining csDMARDs: some studies and systematic reviews support their use \[[@bib0035], [@bib0037]\]; other studies and guidelines question their value \[[@bib0038], [@bib0039]\]. The use of csDMARDs and biologics in TITRATE cannot resolve this controversy but puts their use into context. Furthermore, forty-five percent of assessed IM consultations demonstrated low/poor fidelity to the taught psychosocial care techniques. Another uncertainty is the frequency of patient assessments. TITRATE aimed for monthly intensive management sessions but less frequent sessions and/or incorporating email/skype consulting methods [@bib0040] may have been sufficient -- and more cost effective. Our exploratory analysis of the impact of the number of sessions of intensive management suggests infrequent assessments appear suboptimal.

TITRATE had two main strengths. First, as a relatively large trial, involving 39 centres, its findings are robust. Second, the predicted and the actual outcomes were similar, showing it to have delivered the expected clinical improvements [@bib0032]. TITRATE had several limitations. Firstly, it did not compare the sustainability of remission between groups \[[@bib0041], [@bib0042]\]: however, assessing standard care patients more often than 6-monthly would mean they were no longer receiving standard care, invalidating them as controls. Secondly, TITRATE only lasted 12 months: ideally strategy trials would last longer; 10-year results have been reported for the BeSt strategy trial [@bib0043]. But the organisational and funding complexities of long-term follow up made this impractical in TITRATE. Thirdly, there is uncertainty about which outcome is preferable: ACR-EULAR Boolean remissions appear ideal but are rarely achieved; low DAS28-ESR has less benefit but was achieved by almost half the intensive management patients. Finally, intensive management is not always effective; TITRATE was not designed to show how to manage non-responders. Failure to respond to intensive treatment, particularly biologics, is common and incurs high healthcare costs.

The intensity of RA drug treatment continues to increase, with more combination csDMARDs and biologics used \[[@bib0010], [@bib0011]\]. This increase resulted in 79% standard care TITRATE patients receiving csDMARDs combinations or biologics; only 21% had DMARD monotherapy. The baseline csDMARDs used reflected English practice at the time, with many patients starting sulphasalazine as an initial csDMARD [@bib0044], and patients needed to receive two different csDMARDs before starting biological treatments. By contrast the previous TICORA trial [@bib0032] showed that 88% standard care patients had DMARD monotherapy. The increasing treatment intensity makes it challenging to compare strategy trials completed years apart. However, unlike the recent negative results from other trials [@bib0014] implementing a treat-to-target approach, by combining health care professionals before they delivered intensive management and by providing psychosocial support together with increasing drug treatment, we found intensive management approaches increase remissions in the modern era.

The findings in TITRATE highlight several uncertainties. Firstly, identifying why many patients do not respond to intensive management; analysis of baseline assessments in TITRATE and similar trials may help identify potential non-responders. Secondly, there is limited information about the optimal duration of intensive management strategies in patients who have responded but not achieved sustained remissions. Long-term follow-up of a previous intensive treatment trial suggests benefits decline over time [@bib0045], implying persisting intensive management may be needed. Thirdly, simple blood tests like the ESR did not help monitor responses in TITRATE. This finding is in keeping with previous research by Kay and colleagues, who reported that ESR levels often failed to correlate with disease activity measured by joint counts and global assessments in a large observational study [@bib0046]; alternative strategies, potentially using multiple measures, may be preferable [@bib0047].

We conclude intensive management using treat-to-target approaches benefits patients with moderate established RA as well as patients with active early disease who have been extensively studied in previous trials. TITRATE therefore supports extending treat-to-target approaches to most RA patients who are not yet in remission or low disease activity states. It also highlights the growing importance of non-pharmacological interventions such as psycho-social support. Although our economic analysis showed intensive management exceeded the cost-effective threshold ranges currently used by UK decision makers (≤£30,000/quality-adjusted life-year gained), this estimate reflected historic biological prices at the time of the trial. Adopting current drug acquisition costs would increase the probability intensive management is cost-effective; estimating the impact of remissions after the trial ended would also increase apparent cost-effectiveness.
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[^1]: Showing mean (standard deviation) or number (%). Subcut=subcutaneous; ESR= Erythrocyte Sedimentation Rate; CDAI= Clinical Disease Activity Index; SDAI= Simple Disease Activity Index; VAS= Visual Analogue Scale; DAS28-CRP= Disease Activity Score For 28 Joints Based On C-Reactive Protein; DAS28-ESR= Disease Activity Score for 28 Joints based on ESR; EQ5D-5L= EuroQol 5 Dimension (5 levels).

[^2]: Patient who had Azathioprine at baseline also had additional HCQ; SSZ= Sulfasalazine; HCQ= Hydroxychloroquine; MTX= methotrexate; LEF= Leflunomide; DMARD=disease-modifying antirheumatic drugs.

[^3]: Adjusted for demographics (age, gender, ethnicity, disease duration), design factors (NHS region) and baseline values; ACR/EULAR Boolean remissions were only adjusted for demographics; standard of care arm was the reference group; OR = odds ratio; CI = confidence intervals.

[^4]: Change from baseline analysed and adjustments made for demographics (age, gender, ethnicity, disease duration) design factors (NHS region) and baseline score; standard of care arm was the reference group; SE =standard errors; CI= 95% confidence Intervals.
